drugset / Trial / NCT04782193
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B Cell Lymphoma
Timeline
- Start
- 2021-05-23
- Primary completion
- 2023-12-31
- Completion
- 2024-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 and CD22 targeted prime CAR- T cells | Cell therapy | — | Intravenous |